Merit Medical (NASDAQ: MMSI) director exercises 21,250 stock options in cash
Merit Medical (NASDAQ: MMSI) director Thomas J. Gunderson exercised stock options to acquire 21,250 shares of common stock on May 20, 2026. He paid cash for the exercise price of $52.17 per share, and no shares were sold in connection with these transactions. Following these exercises, Gunderson directly owns 60,741 shares of common stock, and the exercised option grants now have zero remaining shares.
RSU grant to Merit Medical (MMSI) director adds 3,457 share units
Merit Medical Systems director Scott R. Ward received a routine grant of 3,457 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan. These RSUs, granted at no purchase price, will vest on May 3, 2027, provided Ward continues his service with the company. This compensation-related award is viewed as a neutral event for the broader investment case, aligning director interests with shareholders.
Director at Merit Medical (MMSI) receives 3,457 RSUs equity grant
Merit Medical Systems director Stephen C. Evans was granted 3,457 Restricted Stock Units (RSUs) as part of the company's 2026 Equity Incentive Plan. This equity award, which has no cash cost to the director, increases his directly held common shares to 10,266. The RSUs are set to vest on May 3, 2027, provided he continues his service with the company until that date.
Merit Medical (NASDAQ: MMSI) director granted 3,457 RSUs, total holdings 8,040 shares
Merit Medical Systems Inc. (NASDAQ: MMSI) director Silvia M. Perez was granted 3,457 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan. These RSUs will vest on May 3, 2027, subject to her continued service, increasing her direct holdings to 8,040 shares. This transaction was reported via a Form 4 filing and represents an equity grant rather than an open-market purchase.
Merit Medical (NASDAQ: MMSI) director granted 3,457 RSUs under 2026 equity plan
Merit Medical Systems (NASDAQ: MMSI) director Laura S. Kaiser was granted 3,457 Restricted Stock Units (RSUs) under the company's 2026 Equity Incentive Plan. This grant, valued at $0.00 per share, is a form of compensation and not an open-market transaction. The RSUs will vest on May 3, 2027, provided she continues her service to the company, bringing her total direct holdings to 13,352 shares.
Merit Medical (NASDAQ: MMSI) director granted 3,457 RSUs and holds options
Merit Medical Systems Inc. director Thomas J. Gunderson was granted 3,457 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan, which will vest on May 3, 2027, contingent on his continued service. Following this award, Gunderson holds 39,491 shares of Common Stock and stock options for an additional 21,250 shares at an exercise price of $52.17. The filing is categorized as neutral in terms of impact and sentiment.
Director receives 3,457 RSUs at Merit Medical (NASDAQ: MMSI)
Merit Medical Systems Inc. director F. Ann Millner was granted 3,457 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan. These RSUs are scheduled to vest on May 3, 2027, provided her continuous service to the company. Following this compensation-related grant, her direct holdings in the company's common stock amount to 38,000 shares.
Merit Medical Updates Governance and Elects New Director
Merit Medical Systems shareholders approved new equity and stock purchase plans, updated bylaws to enhance governance, and re-elected directors. The company also announced the election of Scott R. Ward to its board, reinforcing its leadership and strategic direction. An analyst has a Buy rating on MMSI with a $96.00 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to strong financial performance offset by weak technical conditions and a demanding valuation.
Merit Medical (NASDAQ: MMSI) holders okay 2026 equity and ESPP plans
Merit Medical Systems, Inc. shareholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan at their annual meeting. The plans allow for stock-based awards and enable eligible employees to purchase common stock at a discount, respectively. Shareholders also re-elected directors, endorsed executive compensation, and ratified Deloitte & Touche LLP as the independent accounting firm for 2026.
Merit Medical (MMSI) director Scott R. Ward files initial Form 3 ownership
Merit Medical Systems Inc. director Scott R. Ward has filed an initial Form 3, which is a statement of beneficial ownership. This filing establishes his baseline disclosure as a reporting person for the company, indicating no reported transactions or derivative positions. The document itself shows his beneficial ownership to be zero, acting as an initial inventory sheet for his holdings.
Scott R. Ward, ex-Medtronic leader, joins Merit Medical board
Merit Medical Systems (NASDAQ: MMSI) announced that shareholders elected Scott R. Ward to its Board of Directors for a three-year term at their annual meeting on May 19, 2026. Ward, an executive with over 40 years of experience in the healthcare and medical device industry, including senior roles at Medtronic and as CEO of Cardiovascular Systems, will serve on the Board’s Governance and Sustainability and Finance and Operating Committees. This appointment is expected to provide valuable strategic insight and support the company's long-term growth and innovation goals.
Merit Medical Systems Elects Scott R. Ward to Board of Directors
Merit Medical Systems, Inc. has elected Scott R. Ward to its Board of Directors for a three-year term, effective May 19, 2026. Ward brings over 40 years of experience in the medical device industry, including leadership roles at Medtronic and as CEO of Cardiovascular Systems, Inc. He will serve on the Governance and Sustainability and Finance and Operating Committees, contributing his strategic insights to the company's innovation and growth initiatives.
Press Release: Merit Medical Shareholders Elect Scott R. Ward to Board of Directors
Merit Medical Systems, Inc. announced that its shareholders elected Scott R. Ward to the company's Board of Directors during its 2024 annual meeting. The appointment of Mr. Ward, who brings extensive experience from his leadership roles at Boston Scientific Corporation, expands the Board to twelve members. His expertise is expected to contribute to Merit Medical's ongoing growth and strategic objectives.
Merit Medical Systems Director Lynne N. Ward Sells 5,000 Shares in Open-Market Transaction
Merit Medical Systems Director Lynne N. Ward sold 5,000 shares of the company's stock in an open-market transaction, according to an SEC filing. The sale generated approximately $313,000 at a weighted average price of $62.61 per share, reducing Ward's direct ownership stake by 39% from 12,809 to 7,809 shares. This is her only open-market transaction in the past year, reflecting a trend of reducing her position, though she still holds shares worth about $489,000.
Merit Medical Systems (MMSI) Valuation Check After New US$270.135 Million Shelf Registration And Guidance Update
Merit Medical Systems (MMSI) recently filed a US$270.135 million shelf registration for common shares and raised its 2026 revenue guidance, yet its stock price has declined significantly. The company is considered undervalued at a 36% discount to its intrinsic value and 48% below analyst targets, primarily due to operational efficiency, product expansion, and regulatory support. However, delays in WRAPSODY CIE reimbursement and rising operating costs pose potential risks to the margin story, while its P/E ratio is still above the industry average.
Thrivent Financial for Lutherans Sells 17,162 Shares of Merit Medical Systems, Inc. $MMSI
Thrivent Financial for Lutherans reduced its stake in Merit Medical Systems by 2.3% in the fourth quarter, selling 17,162 shares to hold 732,904 shares valued at $64.6 million. Despite a recent dip in stock price, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a $92.80 price target. Merit Medical recently surpassed quarterly EPS and revenue expectations and has set a positive FY2026 EPS guidance.
Bessemer Group Inc. Buys 110,392 Shares of Merit Medical Systems, Inc. $MMSI
Bessemer Group Inc. significantly increased its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 54.2% in the fourth quarter, acquiring an additional 110,392 shares to bring its total holding to 313,981 shares valued at approximately $27.7 million. Merit Medical Systems also reported better-than-expected quarterly earnings, with EPS of $0.94 and revenue of $381.9 million, surpassing analyst estimates. Despite some recent price target adjustments by analysts, the stock maintains a "Moderate Buy" consensus rating with a target price of $92.80.
How Investors May Respond To Merit Medical Systems (MMSI) Q1 Beat, Higher 2026 Revenue Outlook, Mixed Insider Moves
Merit Medical Systems (MMSI) reported a strong Q1 2026 with sales of US$381.88 million and net income of US$41.00 million, leading to an upgraded full-year 2026 revenue guidance of US$1.61 billion–US$1.63 billion. This positive financial performance is accompanied by mixed insider activity, with a director selling shares while senior executives purchased through 401(k) plans. The article explores how this improved outlook affects the company's investment narrative, considering both opportunities and risks like product recalls and tariff pressures.
Merit Medical CCO Smith acquires $99,186 in company stock
Christian Adam Smith, Chief Commercial Officer at Merit Medical Systems Inc. (NASDAQ:MMSI), acquired 1,626 shares of company stock worth $99,186 on May 11, 2026, through a 401(k) Plan. This purchase occurred as the stock traded near its 52-week low. The company recently reported strong Q1 2026 financial results, exceeding analyst expectations, and has received various analyst ratings and price targets.
Merit Medical CCO Smith acquires $99,186 in company stock
Merit Medical Systems CCO Christian Adam Smith acquired 1,626 shares of company stock for $99,186 on May 11, 2026, through a 401(k) Plan. This purchase occurred when the stock was near its 52-week low, raising his indirect ownership to 2,220 shares and direct ownership to 30,334 shares. The company recently reported strong Q1 2026 financial results exceeding analyst expectations, with some analysts reiterating positive ratings despite some price target adjustments.
Merit Medical (MMSI) CCO buys 1,626 shares and reports option holdings
Merit Medical Systems Inc.'s Chief Commercial Officer, Christian Adam Smith, reported an open-market purchase of 1,626 shares of common stock at $61.00 per share, through a 401(k) plan, on May 11, 2026. This transaction increased his indirect 401(k) holdings to 2,220 shares. Additionally, Smith holds 30,334 shares directly and also possesses non-qualified stock options for 25,000 shares expiring in 2028 and 8,259 shares expiring in 2030.
Merit Medical Systems stock (US59001A1025): Director sells $313K in shares
Merit Medical Systems director Lynne Ward sold 5,000 shares worth $313,035 on May 7, 2026, while the chief legal officer purchased shares. The company reported strong Q1 revenue of $381.9 million, exceeding estimates, and provided 2026 revenue guidance of $1.61-$1.63 billion. Merit Medical Systems, listed on Nasdaq under MMSI, specializes in disposable medical devices for interventional and diagnostic procedures, with key revenue drivers in peripheral and cardiac interventions and endoscopy.
Merit Medical Systems chief legal officer buys $125,250 in stock
Merit Medical Systems' Chief Legal Officer and Secretary, Brian G. Lloyd, purchased 2,000 shares of company stock worth $125,250 through a 401(k) plan. This transaction occurred on May 7, 2026, when the stock was trading near its 52-week low. The company recently reported strong Q1 2026 financial results, exceeding analyst expectations, though some analysts have adjusted price targets due to various factors.
Merit Medical Systems director Lynne Ward sells $313,035 in stock
Lynne N. Ward, a director at Merit Medical Systems Inc. (NASDAQ:MMSI), sold 5,000 shares of the company's common stock for a total of $313,035 on May 7, 2026. This sale occurred while the stock was trading near its 52-week low. Despite the stock's recent weakness, InvestingPro analysis indicates it is undervalued, even as the company reported strong Q1 2026 financial results exceeding analyst expectations.
Merit Medical Systems Insider Sold Shares Worth $313,035, According to a Recent SEC Filing
An insider at Merit Medical Systems (MMSI) recently sold 5,000 shares of the company's stock for a total value of $313,035. This transaction was disclosed in a Form 4 filing with the SEC.
Insider Sell: Lynne Ward Sells 5,000 Shares of Merit Medical Sys
Lynne Ward, a Director at Merit Medical Systems Inc (MMSI), sold 5,000 shares of the company on May 7, 2026, reducing her holdings to 7,809 shares. This transaction is part of a pattern for Ward, who has sold 10,433 shares over the past year without any purchases. The stock, trading at $62.61, is deemed significantly undervalued with a price-to-GF-Value ratio of 0.65, despite its P/E ratio of 26.28 being slightly above the industry median.
Is Merit Medical Systems (MMSI) Pricing Look Attractive After Steep One Year Share Price Slide
Merit Medical Systems (MMSI) has seen a significant share price decline over the past year, prompting a re-evaluation of its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 34.2% at its current price of US$62.33, indicating an intrinsic value of $94.79 per share. However, its current P/E ratio of 26.69x is above the industry average and Simply Wall St's Fair Ratio of 21.72x, pointing to it being overvalued by this metric.
Merit Medical outlines 2026 constant-currency revenue growth of 5.6% to 7% while integrating $140M View Point Medical deal
Merit Medical is projecting a constant-currency revenue growth of 5.6% to 7% for 2026. This forecast comes as the company plans to integrate its recent $140 million acquisition of View Point Medical. The outlook provides insight into Merit Medical's financial strategy and expected performance in the coming years.
Merit Medical Systems director Lynne Ward sells $313,035 in stock
Merit Medical Systems director Lynne Ward sold 5,000 shares of company stock for $313,035 on May 7, 2026, reducing her direct holdings to 7,809 shares. This sale occurred while the stock was trading near its 52-week low. Despite the sale, the company recently reported strong Q1 2026 financial results, exceeding earnings and revenue expectations, though analysts have adjusted price targets due to concerns like deal dilution.
CLO of Merit Medical (MMSI) adds 2,000 shares via 401(k) plan
Brian G. Lloyd, Chief Legal Officer of Merit Medical (MMSI), reported an indirect purchase of 2,000 shares of common stock through a 401(k) plan on May 7, 2026, at $62.625 per share. This transaction increases his indirect holdings to 2,000 shares, alongside his direct ownership of 62,132 shares and various non-qualified stock options. The filing indicates a positive sentiment regarding this insider activity.
Director at Merit Medical Systems (MMSI) sells 5,000 shares
Lynne N. Ward, a director at Merit Medical Systems (MMSI), sold 5,000 shares of common stock on May 7, 2026, at a weighted average price of $62.607 per share. Following this open-market transaction, Ward now directly holds 7,809 shares. This sale, valued at approximately $313,035, is considered to have a moderate negative impact on filing sentiment.
Piper Sandler Maintains Merit Medical Systems(MMSI.US) With Buy Rating, Maintains Target Price $96
Piper Sandler has reiterated its Buy rating for Merit Medical Systems (MMSI.US) and maintained its target price of $96. This indicates continued confidence in the company's stock performance from the analyst firm.
Piper Sandler reiterates Merit Medical stock rating on growth outlook
Piper Sandler has reiterated an Overweight rating and a $96.00 price target for Merit Medical Systems, Inc. (NASDAQ: MMSI), citing solid growth prospects and strong operational execution. The firm views Merit Medical as a top-three idea due to its financial strength, evidenced by a perfect Piotroski Score of 9, and expects growth acceleration through 2026. This outlook follows Merit Medical's strong first-quarter 2026 financial results, which surpassed analyst expectations for both EPS and revenue.
Merit Medical to Participate in the Bank of America Healthcare Conference
Merit Medical Systems, Inc. announced its management will participate in the Bank of America 2026 Health Care Conference from May 12-14, 2026, in Las Vegas, Nevada. A fireside chat session featuring Merit management will be held on Tuesday, May 12th at 3:00 pm Pacific Time / 6:00 pm Eastern Time, with a live audio webcast available on the company's investor relations website. Merit Medical develops, manufactures, and distributes proprietary medical devices for various interventional and diagnostic procedures worldwide.
Merit Medical (MMSI) CFO adds 1,500 shares at $61.01 purchase price
Merit Medical Systems Inc. (MMSI) Chief Financial Officer and Treasurer Raul Parra Jr. purchased 1,500 shares of company common stock in an open-market transaction on May 6, 2026, at a price of $61.01 per share. Following this purchase, he directly holds 58,843 shares, with additional indirect holdings and non-qualified stock options. This transaction was reported via a Form 4 SEC filing, indicating a neutral filing impact but positive sentiment.
FDA Recall Puts Merit Medical Quality Controls And Growth Story In Focus
Merit Medical Systems faces scrutiny after a nationwide recall of dialysis catheter kits, which include its 16F Dual-Valved Splittable Sheath Introducers, due to a design defect. This recall raises concerns about the company's product quality controls and its relationships with OEM customers, contrasting with its recent positive Q1 2026 sales and raised full-year revenue guidance. Investors are advised to monitor management's response, potential design changes, and the recall's impact on margins and customer contracts relative to Merit's broader growth initiatives in oncology.
Merit Medical to Present at Bank of America Healthcare Conference on May 12, 2026
Merit Medical Systems, Inc. will present at the Bank of America Healthcare Conference on May 12, 2026. This presentation will allow Merit Medical's management to engage with investors and industry stakeholders. The company plans to provide an overview of its strategic initiatives, financial performance, and growth strategies within the healthcare sector.
Merit Medical to Participate in the Bank of America Healthcare Conference
Merit Medical Systems, Inc. announced its management will participate in the Bank of America 2026 Health Care Conference in Las Vegas from May 12-14, 2026. The team will hold a fireside chat on May 12th at 3:00 pm Pacific Time, with a live audio webcast and replay available on the company's investor relations website. Merit Medical develops, manufactures, and distributes proprietary medical devices for interventional, diagnostic, and therapeutic procedures globally.
Insider Buying: Martha Aronson Acquires Shares of Merit Medical Systems Inc (MMSI)
Martha Aronson, President and CEO of Merit Medical Systems Inc (MMSI), recently purchased 2,000 shares, increasing her total holdings to 49,792 shares. The stock is currently trading at $60.44 and is considered significantly undervalued with a price-to-GF-Value ratio of 0.63, despite a higher frequency of insider selling compared to buying over the past year.
[Form 4] MERIT MEDICAL SYSTEMS INC Insider Trading Activity
Merit Medical Systems President and CEO Martha Goldberg Aronson purchased 2,000 shares of the company's common stock at $60.44 per share in an open-market transaction. This acquisition increases her direct ownership to 49,792 shares, signalling a positive sentiment towards the company. The Form 4 filing details this insider trading activity.
[144] MERIT MEDICAL SYSTEMS INC SEC Filing
MERIT MEDICAL SYSTEMS INC (MMSI) has filed a Form 144 notice to offer 5,000 common shares for sale, with a listed date of May 7, 2026. The filing indicates two restricted stock lots from June 2022 and May 2024. The filing also provides details on the securities to be sold, the broker involved, and the acquisition nature of these shares.
Paracentesis Kit Market Is Going to Boom Rapidly | BD, Merit Medical Systems, Cardinal Health, Teleflex Incorporated
The global paracentesis kit market is projected to grow from USD 1.28 billion in 2026 to USD 2.25 billion by 2033, exhibiting an 8.39% compound annual growth rate. This growth is driven by evolving market dynamics, key investment pockets, and regional performance, as analyzed in a comprehensive report by Coherent Market Insights. The report provides detailed insights into market segmentation, competitive landscape, and future opportunities for business leaders and investors.
Merit Medical Systems stock hits 52-week low at $60.50
Merit Medical Systems stock has fallen to a new 52-week low of $60.51, reflecting a 34.69% decrease over the past year despite a perfect Piotroski Score of 9. Analysts have revised earnings downwards, but the company recently reported strong Q1 2026 results, exceeding revenue and EPS expectations. While some analysts have adjusted price targets, InvestingPro suggests the stock may be undervalued.
Merit Medical (MMSI) Is Down 8.0% After Raising 2026 Outlook And Expanding Oncology Platform
Merit Medical Systems (MMSI) saw its stock drop 8.0% despite reporting strong Q1 2026 results, raising its full-year 2026 revenue guidance to US$1.62 billion, and expanding its oncology platform through the Viewpoint Medical acquisition. The company's investment narrative focuses on shifting towards higher-value therapeutic platforms amidst tariffs and OEM volatility, with the new acquisition directly contributing to the raised outlook. While the Q1 beat supports the thesis, the outlook hinges on successful integration and product adoption, with potential risks from tariff costs and reimbursement timing.
MMSI SEC Filings - Merit Med Sys Inc 10-K, 10-Q, 8-K Forms
This page provides access to Merit Medical Systems Inc. (MMSI) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K forms, offering investors detailed financial and operational insights. It highlights recent filings covering earnings, financial guidance, leadership changes, and acquisition activities. Stock Titan offers real-time updates from EDGAR with AI-powered summaries to help users quickly grasp key information.
Needham Adjusts Price Target on Merit Medical Systems to $90 From $101, Maintains Buy Rating
Needham has adjusted its price target for Merit Medical Systems (MMSI) to $90, down from the previous $101, while reiterating a Buy rating on the stock. This revision comes after the company's Q1 results, which showed a slight revenue miss at $317 million compared to the $320 million consensus, despite a solid EBITDA beat. The firm notes that the underlying demand remains strong, particularly for Peripheral Intervention products.
Merit Medical Systems (MMSI) EPS Jump Tests Bullish Margin Expansion Narrative
Merit Medical Systems (MMSI) reported Q1 2026 revenue of US$381.9 million and basic EPS of US$0.69, showing earnings growing faster than revenue with a trailing net margin around 9%. The article explores both bullish and bearish narratives, noting that while EPS growth supports analyst expectations for rising margins, the current pace is slower than the long-term average. Valuation shows MMSI trading at a premium P/E compared to industry averages, raising questions given its moderate projected revenue growth.
Merit Medical Systems Stock To $81?
Merit Medical Systems (MMSI) stock has recently dropped by 12.6%, but Trefis believes it has a strong chance of rebounding to $81 due to its history of recovery post-dips and their "Attractive" opinion of the stock. Historically, MMSI has shown a median return of 34% in the 12 months following sharp dips, with a median peak return of 39%, indicating its resilience and potential for future growth. The company also passes basic financial quality checks, including robust revenue growth and operating cash flow margin.
Merit Medical Systems (NASDAQ:MMSI) Stock Price Down 5.7% on Analyst Downgrade
Merit Medical Systems (NASDAQ:MMSI) saw its stock price drop by 5.7% after Needham & Company LLC lowered its price target from $101 to $90, despite maintaining a buy rating. Several other firms have also trimmed price targets, contributing to a consensus price target of $98.33. This decline occurred despite Merit reporting Q1 earnings that beat expectations, featuring stronger margins, cash flow, and raised FY 2026 EPS guidance, indicating management confidence.
Merit Medical Systems (NASDAQ:MMSI) Given New $85.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group has adjusted its price target for Merit Medical Systems (NASDAQ:MMSI) to $85.00 from $90.00, while maintaining a "buy" rating. This comes despite Merit Medical Systems beating Q1 revenue and EPS estimates and raising its FY2026 EPS guidance, as the stock saw a nearly 9% drop on high volume. Several other analysts have also revised their price targets for MMSI, leading to a consensus "Moderate Buy" rating with an average target price of $92.80.
